PF-07265807 is under clinical development by Pfizer and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PF-07265807’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PF-07265807 is under development for the treatment of advanced or metastatic solid tumors including non-small cell lung cancer, renal cell carcinoma, colorectal cancer, gastric cancer, GEJ adenocarcinoma, cervical cancer, esophageal cancer, endometrial cancer, liver cancer, melanoma, merkel cell carcinoma, head and neck cancer squamous cell carcinoma, small-cell lung cancer, kidney cancer (renal cell cancer), transitional cell carcinoma (urothelial cell carcinoma). It acts by targeting tyrosine protein kinase Mer and AXL kinase.
Pfizer discovers, develops, manufactures and commercializes biopharmaceuticals. The company offers products to treat various conditions such as cardiovascular, metabolic and pain, cancer, inflammation, immune disorders and rare diseases. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, clinics, government agencies and pharmacies. It has major manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. The company provides its products in North America, South America, Asia-Pacific, Australia, Europe, Africa and the Middle East. Pfizer is headquartered in New York, the US.
For a complete picture of PF-07265807’s drug-specific PTSR and LoA scores, buy the report here.